

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MADGE *et al.*

Appl. No.: 10/658,971

Filed: September 9, 2003

For: **Boronic Acid Salts Useful in
Parenteral Formulations**

Confirmation No.: 3998

Art Unit: 1614

Examiner: KWON, Brian Yong S.

Atty. Docket: 2451.0090008/BJD/GER

**Tenth Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on this Tenth Supplemental Information Disclosure Statement are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. This Tenth Supplemental Information Disclosure Statement is a continuation of the Applicants' Ninth Information Disclosure Statement filed on August 7, 2007, in connection with the above-captioned application.

A copy of document **NPL2** is submitted. In accordance with the recent Federal Circuit decision in *Dayco Prods., Inc. v. Total Containment, Inc.* 329 F.3d 1358 (Fed. Cir. 2003), Applicants submit herewith as document **NPL2** an Office Action from copending U.S. Patent Application No. 10/659,178, which is directed to related technical subject matter.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner indicate in the official file wrapper of this patent application that the document has been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Grant E. Reed". The signature is fluid and cursive, with the first name "Grant" and last name "Reed" clearly distinguishable.

Grant E. Reed
Attorney for Applicants
Registration No. 41,264

Date: August 9, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

707721_1.DOC